202917-17-7

Basic information

• Product Name: 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4R)-rel- (9CI)
• Synonyms: 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4R)-rel- (9CI);(aphlaR,4R)-4-(4-Fluoro-2-hydroxyphenyl)-alpha-methyl-2,6-bis(1-methylethyl)-5-propyl-3-pyridinemethanol;glucagon receptor antagonists-3;3-PyridineMethanol, 4-(4-fluoro-2-hydroxyphenyl)-.alpha.-Methyl-2,6-bis(1-Methylethyl)-5-propyl-, (.alpha.R,4R)-rel- (9CI);(alphaR,4R)-4-(4-Fluoro-2-hydroxyphenyl)-alpha-methyl-2,6-bis(1-methylethyl)-5-propyl-3-pyridinemethanol
• CAS NO: 202917-17-7
• Molecular Formula: C22H32FNO2
• Molecular Weight: 361.498
• Mol File: 202917-17-7.mol

Chemical Properties

• Boiling Point: 469.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.085
• PKA: 6.96±0.35(Predicted)
• CAS DataBase Reference: 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4R)-rel- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4R)-rel- (9CI)(202917-17-7)
• EPA Substance Registry System: 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4R)-rel- (9CI)(202917-17-7)

Safety Data

• Hazardous Substances Data: 202917-17-7(Hazardous Substances Data)

Usage

Uses

As the provided materials do not specify the exact applications of 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-α-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4R)-rel(9CI), it is not possible to list its uses according to the materials. Further investigation into the compound's properties and potential applications would be necessary to identify its uses in various industries.

Upstream product

• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 470717-48-7 dimethyl 2,6-diisopropyl-4-oxo-2H-pyran-3,5-dicarboxylate 
• 470717-52-3 dimethyl 2,6-diisopropyl-4-methoxy-3,5-pyridine-dicarboxylate 
• 470717-49-8 dimethyl 2,6-diisopropyl-4-hydroxy-3,5-pyridine-dicarboxylate 
• 470717-47-6 dimethyl 2,6-diisopropyl-4-(2'-benzyloxy-4'-fluoro-phenyl)-3,5-pyridinedicarboxylate 
• 618892-25-4 4-(2-benzyloxy-4-fluoro-phenyl)-5-formyl-2,6-diisopropyl-nicotinic acid methyl ester 
• 503559-80-6 4-(2-Benzyloxy-4-fluoro-phenyl)-2,6-diisopropyl-5-((E)-propenyl)-pyridine-3-carbaldehyde 
• 503559-76-0 4-(2-Benzyloxy-4-fluoro-phenyl)-2,6-diisopropyl-5-((E)-propenyl)-nicotinic acid methyl ester 
• 618892-24-3 4-(2-benzyloxy-4-fluoro-phenyl)-5-hydroxymethyl-2,6-diisopropyl-nicotinic acid methyl ester 
• 503559-84-0 1-[4-(2-Benzyloxy-4-fluoro-phenyl)-2,6-diisopropyl-5-((E)-propenyl)-pyridin-3-yl]-ethanol 

Relevant articles and documents

Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists

Optimized substituent patterns in 4-aryl-pyridine glucagon receptor antagonists were merged to produce highly potent derivatives containing both a 3-[(1R)-hydroxyethyl] and a 2′-hydroxy group. Due to restricted rotation of the phenyl-pyridine bond, these analogues exist as four isomers. A diastereoselective methylcopper reaction was developed to facilitate the synthesis, and single isomers were isolated with activities in the range IC50=10-25 nM.

Substituted biphenyls

Substituted biphenyls having glucagon receptor antagonistic activity. Claimed compounds have the formula wherein R1aand R1bindependently represent (C1-C6) alkyl; R2represents (C1-C10) alkyl or substituted (C1-C10) alkyl wherein the substituents are independently from 1 to 3 of —SR7; R7represents phenyl, or substituted phenyl wherein the substituents are independently 1-5 of halogen, trifluoromethyl, (C1-C6) alkyl, (C1-C6) alkoxy, nitro, cyano, or hydroxyl; R3represents substituted (C1-C6) alkyl wherein the substituents are 1-2 hydroxyl groups; G represents a substituent selected from the group consisting of halogen, (C1-C6) alkyl, and OR4wherein R4is H or (C1-C6) alkyl; and y is 0 or an integer of 1-3. Pharmaceutical compositions containing such compounds and methods of treatment of glucagon-mediated conditions by administering such compounds are also claimed.